XERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Xeris Biopharma Holdings Inc (XERS) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown strong revenue growth, its declining net income and EPS, lack of significant positive trading signals, and neutral sentiment from hedge funds and insiders suggest that it is better to hold off on investing for now. Additionally, technical indicators do not provide a clear entry signal, and no significant news or catalysts are present to drive the stock upward in the near term.
The MACD is positive and contracting, RSI is neutral at 63.918, and moving averages are converging, indicating no strong trend. Key resistance levels are at 6.108 and 6.325, with support at 5.757 and 5.405. The stock is trading near its resistance levels, suggesting limited short-term upside.
Revenue increased by 37.06% YoY in Q3 2025, and gross margin improved to 81.57%, up 16.60% YoY.
Net income dropped by -103.95% YoY, and EPS fell by -100.00% YoY. No significant news, hedge fund activity, or insider buying trends. Stock trend analysis suggests a potential -9.89% decline in the next month.
In Q3 2025, revenue increased to $74.38M (up 37.06% YoY), but net income dropped to $621K (-103.95% YoY), and EPS fell to 0 (-100.00% YoY). Gross margin improved to 81.57% (up 16.60% YoY).
No recent analyst rating or price target changes available.
